Neurology: Volume 99, Number 10, September 6, 2022 Exam #1 - Long-Term Efficacy and Safety From an Open-Label Extension of Adjunctive Cenobamate in Patients With Uncontrolled Focal Seizures

About this course

  • Released: 09/06/2022
  • Expires: 09/06/2025

 

LONG-TERM EFFICACY AND SAFETY FROM AN OPEN-LABEL EXTENSION OF ADJUNCTIVE CENOBAMATE IN PATIENTS WITH UNCONTROLLED FOCAL SEIZURES

LEARNING OBJECTIVES:

Upon completion of the article by Klein et al, the participant should be able to:

  • State the median percent seizure frequency reduction over baseline at months 43-48 in this study
  • State what category of treatment-emergent adverse events was most commonly seen in patients who discontinued cenobamate in this study
  • Discuss seizure-freedom rates and tolerability of cenobamate relative to other antiseizure medications found in this study

CORE COMPETENCIES:

The article by Klein et al covers the following core competency:
  • Medical Knowledge

AUTHOR DISCLOSURES:

Refer to Information and Author section available in the Tool Bar for each article.

 

THIS PAGE IS REQUIRED READING BEFORE BEGINNING ALL ACCME-ACCREDITED COURSES

ACCREDITATION STATEMENT

The American Academy of Neurology Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

MISSION STATEMENT/PROGRAM OBJECTIVES

After evaluating a specific article published in Neurology, participants in the CME activity should be able to demonstrate an increase in, or affirmation of, their knowledge of clinical medicine. Participants should be able to evaluate the appropriateness of the clinical information as it applies to the provision of patient care.

PARTICIPANTS

This program is designed for physicians who are involved in providing patient care and who wish to advance their current knowledge of clinical medicine.

AMA CREDIT DESIGNATION STATEMENT

The American Academy of Neurology Institute designates this journal-based-CME activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DISCLOSURES

CME Journal Editors: James W.M. Owens, Jr., MD, PhD: Scientific Advisory Boards: Member of data safety monitoring board, RaSURE study, AADi Bioscience, Inc. Funding for travel or speaker honoraria: Honoraria, Program Director, AAN Annual Meeting. Editorial Boards: CME Editor, Neurology and Adam Kelly, MD: Editorial Boards: Neurology, CME editor, ongoing since January 2016. Other activities: Question writing for American Academy of Neurology activities, including Continuum. AAN staff members editing the test (K. Aman Ramm) have no disclosures. All relevant financial relationships have been mitigated.

COMMERCIAL SUPPORT

This CME program receives no commercial support.

ACCME